Thomas K Kilvaer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7979876/publications.pdf

Version: 2024-02-01

304368 315357 2,008 37 22 38 h-index citations g-index papers 39 39 39 3385 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 789-800.	0.5	401
2	Stromal CD8+ T-cell Densityâ€"A Promising Supplement to TNM Staging in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2635-2643.	3.2	269
3	Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology, 2016, 27, 225-232.	0.6	147
4	Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia, 2019, 21, 282-293.	2.3	117
5	Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas. PLoS ONE, 2011, 6, e14611.	1.1	96
6	Assessing PDL-1 and PD-1 in Non–Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer, 2017, 18, 220-233.e8.	1.1	72
7	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology, Immunotherapy, 2017, 66, 1449-1461.	2.0	69
8	CD45RO+ Memory T Lymphocytes â€" a Candidate Marker for TNM-Immunoscore in Squamous Nonâ€"Small Cell Lung Cancer. Neoplasia, 2015, 17, 839-848.	2.3	62
9	Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers. PLoS ONE, 2015, 10, e0134965.	1.1	61
10	Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer. Oncotarget, 2016, 7, 72184-72196.	0.8	54
11	Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non–small cell lung cancer. Human Pathology, 2018, 79, 188-198.	1.1	49
12	LAG-3 in Non–Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival. Clinical Lung Cancer, 2018, 19, 249-259.e2.	1.1	48
13	Prognostic relevance of estrogen receptor $\hat{l}\pm$, \hat{l}^2 and aromatase expression in non-small cell lung cancer. Steroids, 2016, 113, 5-13.	0.8	44
14	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 2021, 124, 1680-1689.	2.9	37
15	Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer. PLoS ONE, 2018, 13, e0192157.	1.1	35
16	Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas. PLoS ONE, 2012, 7, e47068.	1.1	33
17	Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis. PLoS ONE, 2010, 5, e15368.	1.1	32
18	Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clinical Pathology, 2012, 12, 5.	1.8	32

#	Article	IF	Citations
19	Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer, 2015, 15, 441.	1.1	31
20	The Prognostic Impact of TGF-Î ² 1, Fascin, NF-Î ⁹ B and PKC-ζ Expression in Soft Tissue Sarcomas. PLoS ONE, 2011, 6, e17507.	1.1	30
21	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. British Journal of Cancer, 2016, 114, 1145-1151.	2.9	25
22	A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Scientific Reports, 2018, 8, 8549.	1.6	24
23	Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clinical Pathology, 2012, 12, 7.	1.8	23
24	High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. Oncolmmunology, 2012, 1, 75-77.	2.1	22
25	The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. Journal of Translational Medicine, 2011, 9, 200.	1.8	20
26	Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC. Scientific Reports, 2019, 9, 10163.	1.6	20
27	Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma. Sarcoma, 2012, 2012, 1-10.	0.7	19
28	Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?. Carcinogenesis, 2020, 41, 1671-1681.	1.3	18
29	The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer. PLoS ONE, 2017, 12, e0181527.	1.1	18
30	Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival. Sarcoma, 2010, 2010, 1-10.	0.7	17
31	Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. International Journal of Oncology, 2011, 38, 1031-40.	1.4	17
32	Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. Journal of Translational Medicine, 2011, 9, 104.	1.8	17
33	The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clinical Pathology, 2014, 14, 5.	1.8	17
34	Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer—A Multi-Institutional Study. Cancers, 2021, 13, 4096.	1.7	11
35	Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis. PLoS ONE, 2015, 10, e0132481.	1.1	11
36	A Pragmatic Machine Learning Approach to Quantify Tumor-Infiltrating Lymphocytes in Whole Slide Images. Cancers, 2022, 14, 2974.	1.7	5

#	Article	IF	CITATIONS
37	Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas. BMC Clinical Pathology, 2013, 13, 9.	1.8	4